Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026 Feb 22, 2025 03:50 HKT/SGT Read More
エーザイ、優れた人的資本経営・情報開示に取り組む企業として「人的資本リーダーズ 2024」「人的資本経営品質 ゴールド」に2年連続で選出 Feb 20, 2025 15:00 JST Read More
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease Feb 14, 2025 11:09 HKT/SGT Read More
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 2024 Feb 12, 2025 08:00 HKT/SGT Read More
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment Feb 04, 2025 18:00 HKT/SGT Read More
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies Feb 03, 2025 16:23 HKT/SGT Read More
国立長寿医療研究センターとエーザイ、認知機能低下リスクの低減と栄養に関するガイダンス、および 宅配食/ミールキット開発の手引きを作成し、食品関連企業へ提供開始 Feb 03, 2025 10:40 JST Read More
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Jan 28, 2025 08:46 HKT/SGT Read More
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Jan 15, 2025 09:03 HKT/SGT Read More
エーザイとバイオジェン・インク、早期アルツハイマー病治療剤「レケンビ(R)」の皮下注射製剤維持投与に関する 生物製剤承認申請を米国FDAが受理 Jan 14, 2025 10:00 JST Read More